about
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.Fatal thrombocytopenia and thrombocytopathia: an unusual onset of non-small cell lung cancer.Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree.Controversies in breast cancer: the mammalian target of rapamycin as a target for breast cancer therapy.Gastric stump lymphoma five years after distal gastrectomy.Docetaxel in advanced gastric cancer--review of the main clinical trials.Platinum salts in advanced breast cancer: a systematic review and meta-analysis of randomized clinical trials.New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials.Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltrationRole of patient and tumor characteristics in sentinel lymph node metastasis in patients with luminal early breast cancer: an observational study.Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials.SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies.International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013).Targeted therapies in breast cancer: where are we now?Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients.Management of breast cancer with targeted agents: importance of heterogeneity. [corrected].Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts.International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010).Heart to heart with trastuzumab: a review on cardiac toxicity.Management of the axilla in early breast cancer patients in the genomic era.Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications.microRNAs in breast cancer development and treatment.Targeted therapy-induced diarrhea: A review of the literature.Neoadjuvant treatment of HER2 and hormone-receptor positive breast cancer - moving beyond pathological complete response.RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.Complete remission in metastatic breast cancer: expecting the unexpected-results of a cross-sectional study.Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial.Trastuzumab cardiac toxicity: a problem we put our heart into.Better Together: Targeted Combination Therapies in Breast Cancer.Vinorelbine With Capecitabine, an Evergreen Doublet for Advanced Breast Cancer: A Systematic Literature Review and Pooled-Analysis of Phase II-III Studies.HER2-Positive Neuroendocrine Breast Cancer: Case Report and Review of Literature.How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case.Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.Ten-year results of applying an original scoring system for addressing adjuvant therapy use after breast-conserving surgery for ductal carcinoma in situ of the breast.Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide.Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer.Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
P50
Q27851451-F47275E8-DCE7-4344-9155-DBE1F624B61EQ27851705-EB0FEE1C-1B42-48EC-B999-834BC5F7894AQ30758991-AD8E674E-EE89-4300-9F4F-210C22EA1D6AQ33348832-44038CDD-07F4-4CC3-A4BB-08A54B635860Q33367641-648FF707-4641-4530-8C5B-578E8C1FC785Q33555591-79430E94-A939-49DA-9BE8-A684AFCE96E8Q35104394-88B5998B-99B1-4760-99D0-EABC36AC28DEQ35613504-0A45A7F9-637E-4BB1-A398-E1E4D07236D6Q36171900-D5B845F1-CBFF-4822-84EE-F0186D54509AQ36223219-F206D924-1325-4570-B0B2-B9D5ED0D1991Q36414012-89E5061F-516D-4F1E-A78B-39B9B4A27315Q36541378-DBF1E931-2512-4E95-A97E-10EBF0ADDFA8Q36614435-A1CF634A-74C6-4EB6-8D75-2ABE5EC1CB83Q37148642-1E3BF987-BC8E-4C3D-95D7-2EE4BA11EE9DQ37152291-9D24B516-7755-41EC-BD9D-DD2FB6E99D41Q37228051-D20186D2-4023-409C-8CEB-52158F10CFB6Q37327300-85D52832-647A-474B-9871-A7BFA1AED845Q37444430-D4AEE3CB-28C1-4268-8FAA-2930A9F642FBQ37686055-A3E75147-810D-41ED-A173-6C6DADE7335CQ37708733-0A3F41D6-1BF9-42FE-B85B-9C324D4EEA8AQ37951426-C2BDBD41-1816-474E-8858-FEE9A58B4089Q37962451-DDBA6991-AA16-4CDB-BFEC-8C55E45E5F46Q38061094-D9B71597-3B2F-42DD-A248-A666A7627A21Q38125970-D834F6E5-F05D-49C7-B284-88059101E681Q38167067-C8159F50-FD6E-4D2F-8808-B4F4BD4A0145Q38174378-2F23A90D-4C6E-47FA-9FB5-B2A47280C889Q38176121-3837CADF-0E64-48A0-BCC6-381649FFF900Q38387030-323E0EE8-148F-47AB-8ECD-7559ACEBAB25Q38403463-63D12BC8-B357-42D7-92B0-C1D17A5461C5Q38422177-1909E130-E7CB-4507-9246-6AC820222838Q38583010-B909B86D-C494-4C78-896C-351EED00F461Q38651714-B3A3E085-1B5E-48F1-A795-F0D1F0E89113Q38860540-663CC4CD-4175-4899-82E9-E6FCCEFCDEA9Q39147165-494C55CD-246C-44F2-9436-94593AD94D20Q39262168-FDC402DA-A497-4402-916F-5DDCB45EF606Q40144433-666A8856-4F01-414B-A7A4-E6A5DDB52A57Q40145267-65D6B1A9-841D-41F5-921B-927A6B63B46AQ40499959-A0A4F714-E19A-4118-A3C2-DDF0A72DA67AQ40502288-23FFBDE8-5AF4-46F5-9BB5-8960957E8BBEQ40505812-992CB369-7534-4BFD-9C3A-9F05205873E6
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Serena Di Cosimo
@ast
Serena Di Cosimo
@en
Serena Di Cosimo
@es
Serena Di Cosimo
@nl
Serena Di Cosimo
@sl
type
label
Serena Di Cosimo
@ast
Serena Di Cosimo
@en
Serena Di Cosimo
@es
Serena Di Cosimo
@nl
Serena Di Cosimo
@sl
prefLabel
Serena Di Cosimo
@ast
Serena Di Cosimo
@en
Serena Di Cosimo
@es
Serena Di Cosimo
@nl
Serena Di Cosimo
@sl
P1053
E-9418-2017
P106
P1153
16244604000
P21
P31
P3829
P496
0000-0002-4666-8052